Table of Content

Open Access iconOpen Access

REVIEW

Interleukin-18: a regulator of cancer and autoimmune diseases

Maryam Esmailbeig1, Abbas Ghaderi1,2

1 Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences
2 Department of Immunology, School of Medicine Shiraz University of Medical Science, Shiraz Iran

* Corresponding Author: A Ghaderi, email

European Cytokine Network 2017, 28(4), 127-140. https://doi.org/10.1684/ecn.2018.0401

Abstract

Interleukin (IL)-18, structurally similar to IL-1β, is a member of IL-1 superfamily of cytokines. This cytokine, which is expressed by many human lymphoid and nonlymphoid cells, has an important role in inflammatory processes. The main function of IL-18 is mediated through induction of interferon-γ (IFN-γ) secretion from T helper (Th1) cells. This cytokine synergistically with IL-12 contributes to Th1 differentiation and, therefore, is important in host defense mechanisms against intracellular bacteria, viruses, and fungi. Recent evidences showing the involvement of IL-18 in Th2 differentiation and ultimately IgE production from B cells have shed a new insight on the dual effects of IL-18 on Th1 and Th2 inflammatory responses. IL-18 in combination with IL-12 can activate cytotoxic T cells (CTLs), as well as natural killer (NK) cells, to produce IFN-γ and, therefore, may contribute to tumor immunity. The biological activity of IL-18 is not limited to these cells, but it also plays a role in development of Th17 cell responses. IL-18 synergistically with IL-23 can induce IL-17 secretion from Th17 cells. The diverse biological activity of IL-18 on T-cell subsets and other immune cells has made this cytokine a good target for investigating its role in various inflammatory-based diseases. Lately, the discovery of IL-18 binding protein (IL-18BP), a physiological inhibitor of IL-18 and a hallmark of IL-18 biology, made this cytokine an attractive target for studying its pros and cons in the treatment of various diseases. In recent years, the biology, genetics, and pathological role of IL-18 have been studied in a number of diseases. In this article, we aimed to present an updated review on these aspects regarding the contribution of IL-18 to important diseases such as cancer, autoimmunity, and inflammatory-mediated conditions including allergic diseases, metabolic syndrome, and atherosclerosis. Emerging data indicating prognostic, diagnostic, and therapeutic features of IL-18 and its related molecules will also be discussed.

Keywords

IL-18, cancer, autoimmunity

Cite This Article

APA Style
Esmailbeig, M., Ghaderi, A. (2017). Interleukin-18: a regulator of cancer and autoimmune diseases. European Cytokine Network, 28(4), 127–140. https://doi.org/10.1684/ecn.2018.0401
Vancouver Style
Esmailbeig M, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. Eur Cytokine Network. 2017;28(4):127–140. https://doi.org/10.1684/ecn.2018.0401
IEEE Style
M. Esmailbeig and A. Ghaderi, “Interleukin-18: a regulator of cancer and autoimmune diseases,” Eur. Cytokine Network, vol. 28, no. 4, pp. 127–140, 2017. https://doi.org/10.1684/ecn.2018.0401



cc Copyright © 2017 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 24

    View

  • 12

    Download

  • 0

    Like

Share Link